Resonant Therapeutic

About

supports the drug discovery sector with a proprietary laboratory tool, IMPaCT (Integrated Microenvironment Pathway Catalog and Triage). The IMPaCT platform combines proprietary tumor models with targeted antibody-based discovery to identify tumor-selective targets and potential therapeutics that are missed by traditional approaches. Therapeutic antibodies (for example, Humira) are applicable to a wide range of diseases and are the largest class of commercial drug therapies on the market currently. Resonant’s business model is to identify new disease targets and drug candidates and to license to large pharmaceutical companies.